
TY  - JOUR
TI  - Abstracts
JO  - Fundamental & Clinical Pharmacology
VL  - 22
IS  - s1
SN  - 0767-3981
UR  - https://doi.org/10.1111/j.1472-8206.2008.00575.x
DO  - doi:10.1111/j.1472-8206.2008.00575.x
SP  - 1
EP  - 102
PY  - 2008
ER  - 

TY  - JOUR
AU  - Laga, Alvaro
AU  - Kurtis, Jonathan
AU  - Sweeney, Joseph
TI  - Recurrent transfusion-related acute lung injury after fresh frozen plasma in a patient with hereditary factor V deficiency
JO  - American Journal of Hematology
JA  - Am. J. Hematol.
VL  - 83
IS  - 8
SN  - 0361-8609
UR  - https://doi.org/10.1002/ajh.21164
DO  - doi:10.1002/ajh.21164
SP  - 680
EP  - 680
PY  - 2008
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Transfusion Medicine
JA  - Transfusion Med
VL  - 27
IS  - S1
SN  - 0958-7578
UR  - https://doi.org/10.1111/tme.12417
DO  - doi:10.1111/tme.12417
SP  - 22
EP  - 71
PY  - 2017
ER  - 

TY  - JOUR
AU  - Rubinstein, Paul G.
AU  - Chen, Yi-Hsiang
TI  - Delayed hemolysis after intravenous anti-D immune globulin infusion in a patient with idiopathic thrombocytopenic purpura
JO  - American Journal of Hematology
JA  - Am. J. Hematol.
VL  - 83
IS  - 8
SN  - 0361-8609
UR  - https://doi.org/10.1002/ajh.21201
DO  - doi:10.1002/ajh.21201
SP  - 684
EP  - 685
PY  - 2008
ER  - 

TY  - JOUR
AU  - Romani, Claudio
AU  - Pettinau, Martina
AU  - Dessalvi, Paolo
AU  - Murru, Roberta
AU  - Angelucci, Emanuele
TI  - Unexpected CNS localization in M2 acute myeloid leukemia: A link with past heroin addiction?
JO  - American Journal of Hematology
JA  - Am. J. Hematol.
VL  - 83
IS  - 8
SN  - 0361-8609
UR  - https://doi.org/10.1002/ajh.21190
DO  - doi:10.1002/ajh.21190
SP  - 682
EP  - 683
PY  - 2008
ER  - 

TY  - JOUR
AU  - D'arena, Giovanni
AU  - Scalzulli, Potito Rosario
AU  - Nobile, Michele
AU  - Dell'olio, Matteo
AU  - Rossi, Giovanni
AU  - Cascavilla, Nicola
TI  - Attenuated doses of rituximab for the treatment of adults with autoimmune cytopenias
JO  - American Journal of Hematology
JA  - Am. J. Hematol.
VL  - 83
IS  - 8
SN  - 0361-8609
UR  - https://doi.org/10.1002/ajh.21203
DO  - doi:10.1002/ajh.21203
SP  - 686
EP  - 687
PY  - 2008
ER  - 

AU  - Singh, Ravindra P.
AU  - Choi, Jeong-Woo
AU  - Tiwari, Ashutosh
AU  - Pandey, Avinash Chand
C7  - pp. 141-197
TI  - Functional Nanomaterials for Multifarious Nanomedicine
SN  - 9781118773512
UR  - https://doi.org/10.1002/9781118773826.ch6
DO  - doi:10.1002/9781118773826.ch6
SP  - 141-197
KW  - Nanomaterials
KW  - nanomedicine
KW  - diagnostics
KW  - therapeutics
KW  - drug delivery
KW  - nanotechnology
KW  - nanoparticles
KW  - medical imaging
KW  - gene therapy
KW  - nanofiber
KW  - toxicity
PY  - 2008
AB  - Summary This chapter contains sections titled: Introduction Nanoparticle Coatings Cyclic Peptides Dendrimers Fullerenes/Carbon Nanotubes/Graphene Functional Drug Carriers MRI Scanning Nanoparticles Nanoemulsions Nanofibers Nanoshells Quantum Dots Nanoimaging Inorganic Nanoparticles Conclusions Acknowledgement
ER  - 

TY  - JOUR
AU  - Holtan, Shernan G.
AU  - Porrata, Luis F.
AU  - Colgan, Joseph P.
AU  - Zent, Clive S.
AU  - Habermann, Thomas M.
AU  - Markovic, Svetomir N.
TI  - mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD)
JO  - American Journal of Hematology
JA  - Am. J. Hematol.
VL  - 83
IS  - 8
SN  - 9781118773512
UR  - https://doi.org/10.1002/ajh.21216
DO  - doi:10.1002/ajh.21216
SP  - 688
EP  - 689
PY  - 2008
ER  - 

TY  - JOUR
TI  - 142nd Annual Meeting of the American Neurological Association
JO  - Annals of Neurology
JA  - Ann Neurol.
VL  - 82
IS  - S21
SN  - 9781118773512
UR  - https://doi.org/10.1002/ana.25024
DO  - doi:10.1002/ana.25024
SP  - S1
EP  - S233
PY  - 2017
ER  - 

TY  - JOUR
TI  - Presentations
JO  - HPB
VL  - 8
IS  - s1
SN  - 9781118773512
UR  - https://doi.org/10.1080/13651820500534892
DO  - doi:10.1080/13651820500534892
SP  - 23
EP  - 87
PY  - 2006
ER  - 

TY  - JOUR
TI  - ABSTRACTS
JO  - Alcoholism: Clinical and Experimental Research
VL  - 21
IS  - s3
SN  - 9781118773512
UR  - https://doi.org/10.1111/j.1530-0277.1997.tb04661.x
DO  - doi:10.1111/j.1530-0277.1997.tb04661.x
SP  - 4A
EP  - 137A
PY  - 1997
ER  - 

TY  - JOUR
TI  - American association for the study of liver diseases
JO  - Hepatology
JA  - Hepatology
VL  - 16
IS  - S4
SN  - 9781118773512
UR  - https://doi.org/10.1002/hep.1840160702
DO  - doi:10.1002/hep.1840160702
SP  - 1A
EP  - 292A
PY  - 1992
ER  - 

TY  - JOUR
TI  - Abstracts 1090 - 1621
JO  - American Journal of Transplantation
VL  - 4
IS  - s8
SN  - 9781118773512
UR  - https://doi.org/10.1111/j.1600-6135.2004.0480c.x
DO  - doi:10.1111/j.1600-6135.2004.0480c.x
SP  - 457
EP  - 604
PY  - 2004
ER  - 

AU  - Singh, Ravindra P.
AU  - Choi, Jeong -Woo
AU  - Tiwari, Ashutosh
AU  - Pandey, Avinash Chand
C7  - pp. 215-262
TI  - Utility and Potential Application of Nanomaterials in Medicine
SN  - 9781118030141
UR  - https://doi.org/10.1002/9781118523025.ch7
DO  - doi:10.1002/9781118523025.ch7
SP  - 215-262
KW  - Nanomaterials
KW  - nanomedicine
KW  - diagnostics
KW  - therapeutic
KW  - drug delivery
KW  - nanotechnology
KW  - nanoparticles
KW  - medical imaging
KW  - gene therapy
KW  - nanofiber
KW  - toxicity
PY  - 2004
AB  - Summary This chapter contains sections titled: Introduction Nanoparticle Coatings Cyclic Peptides Dendrimers Fullerenes/Carbon Nanotubes/Graphene Functional Drug Carriers MRI Scanning Nanoparticles Nanoemulsions Nanofibers Nanoshells Quantum Dots Nanoimaging Inorganic Nanoparticles Conclusion
ER  - 

TY  - JOUR
TI  - Abstracts List
JO  - Journal of Tissue Engineering and Regenerative Medicine
JA  - J Tissue Eng Regen Med
VL  - 7
IS  - s1
SN  - 9781118030141
UR  - https://doi.org/10.1002/term.1822
DO  - doi:10.1002/term.1822
SP  - 6
EP  - 52
PY  - 2013
ER  - 

TY  - JOUR
TI  - POSTER PRESENTATIONS
JO  - Xenotransplantation
VL  - 14
IS  - 5
SN  - 9781118030141
UR  - https://doi.org/10.1111/j.1399-3089.2007.00423.x
DO  - doi:10.1111/j.1399-3089.2007.00423.x
SP  - 449
EP  - 549
PY  - 2007
ER  - 

TY  - JOUR
AU  - Zlotnick, David M.
AU  - Merrens, Edward J.
AU  - Petras, Melissa L.
AU  - Tsongalis, Gregory J.
AU  - Bentley, Heather
AU  - Fingar, Elizabeth L.
AU  - Levy, Norman B.
TI  - Intravascular lymphoma as a recurrence of testicular Non-Hodgkin's lymphoma confirmed by polymerase chain reaction
JO  - American Journal of Hematology
JA  - Am. J. Hematol.
VL  - 83
IS  - 8
SN  - 9781118030141
UR  - https://doi.org/10.1002/ajh.21193
DO  - doi:10.1002/ajh.21193
SP  - 681
EP  - 682
PY  - 2008
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Internal Medicine Journal
VL  - 38
IS  - s3
SN  - 9781118030141
UR  - https://doi.org/10.1111/j.1445-5994.2008.01728.x
DO  - doi:10.1111/j.1445-5994.2008.01728.x
SP  - A37
EP  - A70
PY  - 2008
ER  - 

TY  - JOUR
AU  - Anderson, Garth R.
AU  - Stoler, Daniel L.
TI  - Anoxia, wound healing, VL30 elements, and the molecular basis of malignant conversion
JO  - BioEssays
JA  - Bioessays
VL  - 15
IS  - 4
SN  - 9781118030141
UR  - https://doi.org/10.1002/bies.950150407
DO  - doi:10.1002/bies.950150407
SP  - 265
EP  - 272
PY  - 1993
AB  - Abstract Although VL30 retrotransposable elements have been associated with certain cancers for nearly twenty years, because of their expression in rodent malignancies and recombination into murine sarcoma viruses, their causative role, if any, in cancer has been uncertain and enigmatic. Recent findings suggest loss of normal transcriptional control of specific VL30 element expression may make a critical contribution to tumor progression at a step associated with malignant conversion, by bringing into play a cellular program normally involved in wound healing. This program, the fibroblast anoxic response system, includes an adaptation to glycolytic metabolism, secretion of metalloproteinases, and activation of an endonuclease. While appropriate for facilitating debris removal during wound healing, loss of control of this program in a cell which has already progressed to the benign neoplastic state has the potential to simultaneously produce the invasiveness and genomic instability charateristic of malignancy. Examination of tumors and tumor derived cell lines has confirmed that key aspects of this system are in fact activated in cancer.
ER  - 

TY  - JOUR
AU  - Kozuch, P. L.
AU  - Brandt, L. J.
TI  - Review article: diagnosis and management of mesenteric ischaemia with an emphasis on pharmacotherapy
JO  - Alimentary Pharmacology & Therapeutics
VL  - 21
IS  - 3
SN  - 9781118030141
UR  - https://doi.org/10.1111/j.1365-2036.2005.02269.x
DO  - doi:10.1111/j.1365-2036.2005.02269.x
SP  - 201
EP  - 215
PY  - 2005
AB  - Summary Mesenteric ischaemia results from decreased blood flow to the bowel, causing cellular injury from lack of oxygen and nutrients. Acute mesenteric ischaemia (AMI) is an uncommon disorder with high morbidity and mortality, but outcomes are improved with prompt recognition and aggressive treatment. Five subgroups of AMI have been identified, with superior mesenteric artery embolism (SMAE) the most common. Older age and cardiovascular disease are common risk factors for AMI, excepting acute mesenteric venous thrombosis (AMVT), which affects younger patients with hypercoaguable states. AMI is characterized by sudden onset of abdominal pain; a benign abdominal exam may be observed prior to bowel infarction. Conventional angiography and more recently, computed tomography angiography, are the cornerstones of diagnosis. Correction of predisposing conditions, volume resuscitation and antibiotic treatment are standard treatments for AMI, and surgery is mandated in the setting of peritoneal signs. Intra-arterial vasodilators are used routinely in the treatment of non-occlusive mesenteric ischaemia (NOMI) and also are advocated in the treatment of occlusive AMI to decrease associated vasospasm. Thrombolytics have been used on a limited basis to treat occlusive AMI. A variety of agents have been studied in animal models to treat reperfusion injury, which sometimes can be more harmful than ischaemic injury. Chronic mesenteric ischaemia (CMI) usually is caused by severe obstructive atherosclerotic disease of two or more splanchnic vessels, presents with post-prandial pain and weight loss, and is treated by either surgical revascularization or percutaneous angioplasty and stenting.
ER  - 
